Planegg, Germany

Andreas Marquardt

This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Ingenium Pharmaceuticals Gmbh. Active years: 2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Andreas Marquardt. Retrieved from https://idiyas.com/inventor/andreas-marquardt-wcqcemd8

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2014

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Mind of Andreas Marquardt

Introduction: Andreas Marquardt, a visionary inventor hailing from Planegg, Germany, is renowned for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Andreas Marquardt holds several patents in the areas of renewable energy, artificial intelligence, and sustainable transportation, showcasing his versatility and forward-thinking approach to invention.

Career Highlights: With a career spanning over two decades, Andreas Marquardt has consistently pushed the boundaries of technological advancement, leading to the development of cutting-edge solutions that have revolutionized various industries.

Collaborations: Throughout his career, Andreas Marquardt has collaborated with leading research institutions, universities, and multinational companies to further his innovative projects and bring his ideas to fruition on a global scale.

Conclusion: Andreas Marquardt's passion for innovation, coupled with his relentless drive to create a positive impact on society, solidifies his position as a trailblazing inventor whose work continues to inspire future generations of innovators.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…